Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.
| Publicado en: | Journal of Clinical Oncology Vol. 43; pp. 179 - 467 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2/20/2025 Supplement 5
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=183112919&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 183112919 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2/20/2025 Supplement 5 vid: 43 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 183112919 10.1200/JCO.2025.43.5_suppl.179 183112919 ppf: 179 ppct: 288 formats: tig: atl: Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis. aug: au: Freedland, Stephen J. De Giorgi, Ugo Tutrone, Ronald F. Karsh, Lawrence Ivan Ramirez-Backhaus, Miguel Uchio, Edward M. Tang, Yiyun Croitoru, Ruslan Rosales, Matt Kalac, Matko Wang, Fong Shore, Neal D. affil: Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|